Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Biologics yield low rates of skin clearance in real-world psoriasis study

Publish date:: June 3, 2020

Key clinical point: Complete clearance rates with biologic therapies in real-world psoriasis studies may be lower than in clinical trials.

Major finding: At 6 and 12 months respectively, 23% and 26% of patients had achieved a PASI 100 score.

Study details: PSO-BIO-REAL (Plaque Psoriasis Treated With Biologics in a Real World Setting) is a multinational prospective trial that evaluated effectiveness of several biologic therapies in patients with moderate to severe plaque psoriasis.

Disclosures: The study was sponsored by Amgen/AstraZeneca; the manuscript was sponsored by LEO Pharma. One author was an AstraZeneca employee, two are LEO pharma employees, one author had no disclosures, and the remaining authors, disclosed serving as an adviser, paid speaker, consultant, and/or investigator for multiple companies.

Citation:

Seneschal J et al. J Eur Acad Dermatol Venereol. 2020 May 4. doi: 10.1111/jdv.16568.

This Week's Must Reads

Synovial, skin gene expression differences may explain PsA treatment responses,

Guselkumab improvements for psoriatic arthritis persist through 1 year,

Biologics may delay psoriatic arthritis, study finds,

PASDAS beats DAS28 in measuring psoriatic arthritis treat-to-target success,

Entheseal lesions, bone density linked with incident PsA in psoriasis patients,

Must Reads in Psoriasis

Synovial, skin gene expression differences may explain PsA treatment responses,

Biologics may delay psoriatic arthritis, study finds,

Biologics yield low rates of skin clearance in real-world psoriasis study,

Financial incentives affect the adoption of biosimilars,

Genome study examines heritability of psoriatic disease subtypes,